Trial Profile
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Trebananib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Amgen
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2011 Planned End Date changed from 1 Feb 2013 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 25 Jun 2011 Results presented at the 13th World Congress on Gastrointestinal Cancer.